Latest News and Press Releases

Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's...

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global DNA Repair Drugs Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. Emerging Trends and...

DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...

WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...

SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian...

Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "Human Recombinant DNA: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report highlights the current and future market...

Dublin, July 26, 2022 (GLOBE NEWSWIRE) -- The "DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. DNA Damage Response (DDR)...

VANCOUVER, British Columbia, April 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel...

INDIANAPOLIS, March 30, 2022 (GLOBE NEWSWIRE) -- NERx Biosciences, an oncology company led by John Turchi and Katherine Pawelczak, will be presenting on two pre-clinical pipeline drugs that may have...

Dublin, Feb. 25, 2022 (GLOBE NEWSWIRE) -- The "DNA Repair Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report provides an in-depth examination of the...